Division Highlights - Hematology, Oncology & Bone Marrow Transplant
The Division of Hematology, Oncology & Bone Marrow Transplant provides state-of-the-art integrated therapies, including stem cell transplant, aimed at curing malignancies and treating hematological disorders in children.
Research interests include ways to recognize and destroy cancer cells using immunologic and molecular biologic pathways, cancer survivorship, neuro-oncology and palliative care.
- Christian Capitini, MD, received $50,000 from Hyundai’s Hope on Wheels 2011 Scholar Grant for his one-year project, “Development of STAT1 Inhibitors for Treating Pediatric Leukemia and Modulation of Allogeneic Bone Marrow Transplant.” He also received a $100,000 award from the Midwest Athletes Against Childhood Cancer (MACC) fund for his project, “Inhibiting STAT1 as a Platform for GVHD Resistance and Preservation of GVL.”
- Kenneth DeSantes, MD, received $100,000 from the Midwest Athletes Against Childhood Cancer (MACC) fund for a project supporting data management and clinical research coordination for the American Family Children’s Hospital pediatric oncology program, and has led the AFCH in becoming one of only 10 centers in the USA routinely performing 131I-MIBG treatment for neuroblastoma.
- Carol Diamond, MD, was elected to the Alpha Omega Alpha Honor Medical Society, a professional medical organization that recognizes and advocates for excellence in scholarship and the highest ideals in the profession of medicine.
- Mario Otto, MD, PhD, received $100,000 from the MACC fund for his project, “Development of Multifunctional Superparamagnetic Anti-GD2 Nanoparticles for Simultaneous Molecular Imaging, Cancer Cell Targeting and Drug Delivery.”
- Paul Sondel, MD, PhD, received $100,000 from the MACC fund for his project, “Autologous KIR/ KIR-ligand Mismatch, FcγR Polymorphisms and Their Influences on Response to Tumor Targeted Immunocytokine.”
- Tyler Van De Voort, a student in the laboratory of Paul Sondel, MD, PhD, received a 2011-2012 UW Hilldale Undergraduate Research Fellowship.
Professor and Division Chief
Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123. PMID: 21660134.
Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol. 2011 Apr;89(4):625-38. PMID: 21248148.
Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biol Blood Marrow Transplant. 2011 Jun;17(6):790-9. PMID: 21216299.
Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep;28(6):459-60. Review. Erratum in: Pediatr Hematol Oncol. 2011 Oct;28(7):625. PMID: 21854215.
Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. PMID: 21792658.
Jiao P, Zhou H, Otto M, Mu Q, Li L, Su G, Zhang Y, Butch ER, Snyder SE, Jiang G, Yan B. Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J Am Chem Soc. 2011 Sep 7;133(35):13918-21. Epub 2011 Aug 15. PMID: 21827210.
Johnson EJ, Buhtoiarov IN, Baldeshwiler MJ, Felder MAR, Rooijen NV, Sondel PM, Rakhmilevich AL. Enhanced T cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011;34:76-84. PMID: 21150715.
Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor Œ± activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2011 Sep;57(3):398-405. PMID: 21681921.
Mehta M, Vogelbaum MA, Chang S, Patel N. Neoplasms of the central nervous system. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:1700-1749.
Otto M, Shulkin BL, Kundu M, Sandlund JT, Snyder SE, Metzger ML. Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma. J Pediatr Hematol Oncol. 2011 Nov 11. PMID: 22082744.
Russ AJ, Wentworth L, Xu K, Rakhmilevich A, Seroogy CM, Sondel PM, Suresh M, Cho CS. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011 Dec;18(13):3848-57. PMID: 21465311.
Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol. 2011 Nov;11(11):1877-86. PMID: 21854876.
Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8. PMID: 21340652.
Verbsky JW, Baker MW, Grossman WJ, Hintermeyer M, Dasu T, Bonacci B, Reddy S, Margolis D, Casper J, Gries M, Desantes K, Hoffman GL, Brokopp CD, Seroogy CM, Routes JM. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol. 2012 Feb;32(1):82-8. Epub 2011 Nov 10. PMID: 22068910.
Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 1;17(21):6858-66. PMID: 21908574.
|Principal Investigator||Funding Agency||Title|
|Capitini, Christian||Hyundai Motor America||Development of STAT1 Inhibitors For Treating Pediatric Leukemia and Modulation of Allogeneic Bone Marrow Transplant|
|Capitini, Christian||Midwest Athletes Against Childhood Cancer||Inhibiting STAT1 as a Platform for GVHD Resistance and Preservation of GVL|
|DeSantes, Kenneth||Midwest Athletes Against Childhood Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusions for Pediatric Acute Leukemia and High Risk Solid Tumors|
|DeSantes, Kenneth||Midwest Athletes Against Childhood Cancer||Support for Research Data Management|
|DeSantes, Kenneth||National Childhood Cancer Foundation||COG Chairs Grant|
|DeSantes, Kenneth||National Childhood Cancer Foundation||Per Case & Specimen Reimbursement|
|DeSantes, Kenneth||Pfizer, Inc||A Prospective, Open-Label, Non-Randomized, Multi-Center Study to Investigate the Safety and Tolerability of Voriconazole As Primary Therapy for Treatment of Invasive Aspergillosis and Molds such as Scedosporium or Fusarium Species in Pediatric Patients|
|DeSantes, Kenneth||Solving Kids Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusions for Pediatric Acute Leukemia and High Risk Solid Tumors|
|Puccetti, Diane||Midwest Athletes Against Childhood Cancer||Psychosocial Aspects of Ending Treatment & Long-Term Survival of Pediatric Cancer Patients: A Joint Proposal|
|Puccetti, Diane||OSI Pharmaceuticals, Inc||A Randomized, Phase 2 Study of Single-Agent Erlotinib Versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma|
|Puccetti, Diane||OSI Pharmaceuticals, Inc||Open-label, phase 2 study of single-agent Erlotinib for patients with pediatric ependymoma previously treated with oral Etoposide in protocol OSI-774-205|
|Sondel, Paul||American Society of Hematology||The Influence of KIR and HLA Genotype on the Clinical Response to Immunotherapy with Rituximab for Patients with Follicular Lymphoma (Fellowship Support for Dr. B. Grzywacz)|
|Sondel, Paul||Department of Defense||Ovarian Cancer Immunotherapy Using Redirected Endogenous Anti-Gal Antibody|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Antitumor Mechanisms of Anti-CD40/CpG-Activated Macrophages|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Clinical Development of HU14.18-IL2 Targeted Therapy|
|Sondel, Paul||Hyundai Motor America||Genotyping of Killer Inhibitory Receptor (KIR), KIR-Ligrand (KIR-L) and Fc receptor Genesor to Improve the Outcome for Children Receiving Effective Immunotherapy for Neuroblastoma|
|Sondel, Paul||Midwest Athletes Against Childhood Cancer||Autologous KIR/KIR-ligand Mismatch, FcyR Polymorphisms and Their Influences on Response to Tumor-Targeted Immunocytokine|
|Sondel, Paul||National Childhood Cancer Foundation||Neuroblastoma Resource and Reference Laboratory|
|Sondel, Paul||St. Jude Children’s Research Hospital||A Phase I Trial of the Humanized Anti-GD2 Antibody in Children and Adolescents with Neuroblastoma or Melanoma (Laboratory Monitoring)|
|Sondel, Paul||Super Jake Foundation||Multivalent Decoration of Neuroblastoma Cells to Mediate Tumor Destruction|
|Sondel, Paul||UWCCC||KIR and KIR-L Genotyping in Lymphoma|